Sarcopenia
Conditions
Keywords
Sarcopenia, Muscle, Aging, Muscle Protein Synthesis
Brief summary
The age-related decline in muscle mass and strength is collectively referred to as sarcopenia. Canadian recommended daily allowance (RDA) for protein intake (0.8 g/kg/d), however, many expert groups have advocated that older persons should increase their daily intake to \ 1.2 g/kg/d to support the preservation of muscle mass. The use of plant-based proteins in food formulation has recently become of interest. This study will examine the impact of consuming higher- versus lower-quality protein supplements on muscle protein synthesis in healthy older men.
Detailed description
This study will examine the impact of consuming higher- versus lower-quality protein supplements on the integrated rates of muscle protein synthesis in healthy older men. Briefly, participants will consume dietary protein at the RDA for the entire duration of the protocol (2 weeks). Participants will be randomized to consuming collagen (control - CON), whey (WHEY), or pea (PEA) protein supplements twice daily for one week. We will examine the ability of different qualities of protein supplements to stimulate integrated rates of muscle protein synthesis.
Interventions
DIETARY_SUPPLEMENTProtein Supplementation
Participants will continue to ingest the standardized diet; however, supplements will be consumed twice daily (25g per serving x 2 servings/day or 50g supplemental protein/day)
Sponsors
McMaster University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)
Masking description
Participants and the investigators will be blinded to the supplement type, only the Lead Principal Investigator will have the codes to decipher the supplement type. Supplements are referred to as A, B and C.
Intervention model description
The study will be a double blind, randomized parallel group controlled trial.
Eligibility
Sex/Gender
MALE
Age
65 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
1. Men, between the ages of 65 - 80 years (inclusive) 2. Willing and able to provide informed consent 3. Be in general good health, non-smoking 4. Have a body mass index (BMI) between 20-38 kg/m2 (inclusive)
Exclusion criteria
1. Use of tobacco or related products. 2. Veganism or vegetarianism 3. Any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the Investigator, would compromise his/her ability to comply with the study requirements. 4. Use assistive walking devices (e.g., cane or walker) 5. History of cancer within the last 5 years, except basal cell carcinoma, non-squamous skin carcinoma, prostate cancer or carcinoma in situ with no significant progression over the past 2 years. 6. Significant orthopedic, cardiovascular, pulmonary, renal, liver, infectious disease, immune disorder, or metabolic/endocrine disorders or other disease that would preclude oral protein supplement ingestion and/or assessment of safety and study objectives. 7. Any cachexia-related condition (e.g., relating to cancer, tuberculosis or human immunodeficiency virus infection and acquired immune deficiency syndrome) or any genetic muscle diseases or disorders 8. Current illnesses which could interfere with the study (e.g. prolonged severe diarrhea, regurgitation, difficulty swallowing) 9. Hypersensitivity or known allergy to any of the components in the test formulations. 10. Excessive alcohol consumption (\>21 units/week) 11. History of bleeding diathesis, platelet or coagulation disorders, or antiplatelet/anticoagulation therapy (up to 81mg of baby aspirin per day taken as a prophylactic is permitted). 12. History of statin myalgia. 13. Personal or family history of clotting disorder or deep vein thrombosis; 14. Routine/daily usage of non-steroidal anti-inflammatory drugs (NSAIDS, prescription use or daily use of over the counter medication), use of corticosteroids, testosterone replacement therapy (ingestion, injection, or transdermal), any anabolic steroid, creatine, whey protein supplements, casein or branched-chain amino acids (BCAAs) within 45 days prior to screening.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Integrated Muscle Protein Synthesis | 7 days x 2 | Integrated protein synthesis will be determined during 7 days of consuming the RDA of protein (control phase), and during 7 days of supplementation with a randomised protein supplement (Supplement phase). Integrated rates of muscle protein synthesis (MPS) will be determined using the D2O method. Briefly, 2H enrichment of saliva (precursor) and muscle (product) pools (relative to 1H) will be determined using isotope ratio mass spectrometry and 'myofibrillar fractional synthetic rate' (%/day) determined. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Anabolic Signalling Proteins | 1 hour | The effect of each protein supplement on anabolic signalling proteins 1h post-ingestion. Briefly, the phosphorylation status (activation) of anabolic signalling proteins will be determined by western blot analysis, and the fold change from that basal state will be presented. |
Countries
Canada
Outcome results
None listed